Roth MKM resumed coverage of Fortress Biotech with a Buy rating and $10 price target. The company continues to build out a diverse pipeline of “high potential” clinical stage assets, the analyst tells investors in a research note. The firm says Fortress has 25 clinical assets with three nearing approval in 2024, through a diverse portfolio of four public and six private companies. It believes that multiple near-term catalysts could both increase the company valuation and provide non-dilutive capital to fund development costs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FBIO:
- Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
- Fortress Biotech to Participate in 36th Annual ROTH Conference
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
- Fortress Biotech, Cyprium Therapeutics announces $4.1M grant from NINDS
- Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
